| Metric | FY2025 | FY2024 |
|---|---|---|
| General and administrative | $5.6M+260.6% | $1.6M |
| Research and development | $266K+8.0% | $246K |
| Total operating expenses | $5.9M+226.0% | $1.8M |
| Loss from operations | -$5.9M-226.0% | -$1.8M |
| Net gain from change in fair value of derivative liability instrument | $2.6M | — |
| Gain from change in fair value of forward contract liability | $380K | — |
| Amortization of deferred offering cost | -$497K | — |
| Interest income | $30K+3.0% | $29K |
| Other income | $177K | — |
| Total other income | $2.7M+9181.3% | $29K |
| NET LOSS | -$3.2M-80.6% | -$1.8M |
| Basic net loss per common share | -$0.12-71.4% | -$0.07 |
| Diluted net loss per common share | -$0.12-71.4% | -$0.07 |
| Weighted-average common shares outstanding, basic | 27.7M+4.0% | 26.6M |
| Weighted-average common shares outstanding, diluted | 27.7M+4.0% | 26.6M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.